Cargando…

Clonal replacement of novel T cells: a new phenomenon in the tumor microenvironment following PD-1 blockade

Detalles Bibliográficos
Autores principales:	Li, Xue, Wang, Manni, Xiang, Rong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Research Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6813357/ https://www.ncbi.nlm.nih.gov/pubmed/31666993 http://dx.doi.org/10.1038/s41392-019-0077-2

Ejemplares similares

Deletion of the RNA-editing enzyme ADAR1A: new strategy to potentiate responses to PD-1 immune checkpoint blockade
por: Wang, Manni, et al.
Publicado: (2019)

Clonal replacement of tumor-specific T cells following PD-1 blockade
por: Yost, Kathryn E., et al.
Publicado: (2019)

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?
por: Tang, Fei, et al.
Publicado: (2018)

Radiotherapy and the tumor microenvironment: The “macro” picture
por: Walton, Emma Louise
Publicado: (2017)

Fecal microbiota transplantation: can it circumvent resistance to PD-1 blockade in melanoma?
por: Derosa, Lisa, et al.
Publicado: (2021)

Epigenetic checkpoint blockade: new booster for immunotherapy
por: Wang, Ziqiao, et al.
Publicado: (2021)

Digitally deconvolving the tumor microenvironment
por: Aran, Dvir, et al.
Publicado: (2016)

Neoadjuvant PD-1 blockade: a promising nonoperative strategy for mismatch repair–deficient, locally advanced rectal cancer
por: Mi, Mi, et al.
Publicado: (2022)

Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?
por: Chocarro de Erauso, Luisa, et al.
Publicado: (2020)

Serial progression of cortical and medullary thymic epithelial microenvironments
por: Alves, Nuno L, et al.
Publicado: (2014)

Tumor mutational burden as a new biomarker for PD-1 antibody treatment in gastric cancer
por: Folprecht, Gunnar
Publicado: (2019)

Machine Learning for Organic Synthesis: Are Robots Replacing Chemists?
por: Maryasin, Boris, et al.
Publicado: (2018)

CHIPping away at the genetic aetiology of clonal haematopoiesis
por: Minton, Kirsty
Publicado: (2022)

Tumor-draining lymph node-derived tumor-specific memory CD8(+) T cells: a key player in PD-1/PD-L1 immunotherapy
por: Yin, Enzhi, et al.
Publicado: (2023)

What a Clinician Should Know About a Renal Replacement Membrane?
por: Honore, Patrick M., et al.
Publicado: (2018)

Targeting programmed death ligand 2/repulsive guidance molecule b pathway: a novel strategy to subdue tumor immunotherapy resistance to anti‐programmed death 1/programmed death ligand 1
por: Xiang, Yuancai, et al.
Publicado: (2023)

Mechanism of action of PD‐1 receptor/ligand targeted cancer immunotherapy [Image: see text]
por: Borst, Jannie, et al.
Publicado: (2021)

A pan-cancer fingerprint: common molecular denominators of the human tumor microenvironment
por: Ng, Susanna S., et al.
Publicado: (2021)

CAR-T: a potential gene carrier targeting solid tumor immune microenvironment
por: Wang, Minjie, et al.
Publicado: (2021)

A role for complement blockade in kidney transplantation
por: Karpman, Diana, et al.
Publicado: (2022)

‘Nur'turing tumor T cell tolerance and exhaustion: novel function for Nuclear Receptor Nur77 in immunity
por: Lith, Sanne C., et al.
Publicado: (2020)

Neutrophil-sourced TNF in cancer: deciphering an intricate orchestrator of immunosuppressive communication in the tumor microenvironment
por: Zhao, Xinyuan, et al.
Publicado: (2023)

Tumor‐derived microparticles in tumor immunology and immunotherapy
por: Ma, Jingwei, et al.
Publicado: (2020)

Competition for nutrients or cell intrinsic programming? – Metabolic mechanisms behind the tumor promoting immune microenvironment in cancer
por: Niu, Yuequn, et al.
Publicado: (2021)

Selecting suitable chemotherapies for PD-1/PD-L1 blockade to optimize the tumor immune microenvironment
por: Koyama, Shohei, et al.
Publicado: (2018)

Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade
por: Wang, Shuhang, et al.
Publicado: (2022)

Immune responses to tumor-unrelated antigens might predict adverse effects in patients treated with anti-PD-1 immunotherapy
por: Nüse, Björn, et al.
Publicado: (2022)

Ambra1 modulates the tumor immune microenvironment and response to PD-1 blockade in melanoma
por: Frias, Alex, et al.
Publicado: (2023)

Regulation of axonal remodeling following spinal cord injury
por: Jacobi, Anne, et al.
Publicado: (2015)

Segregating memories: targeting microenvironment of neuronal ensembles
por: Liu, Ying, et al.
Publicado: (2022)

Bispecific immune molecule PD1-IL2v: a new therapeutic strategy for pancreatic ductal adenocarcinoma
por: Gao, Yuan, et al.
Publicado: (2023)

Therapeutic targeting of PD-1/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment
por: Acúrcio, Rita C., et al.
Publicado: (2022)

FcγRIIb blockage: a promising immunotherapy target for severe COVID-19
por: He, Xuemei, et al.
Publicado: (2021)

Constrained surfaces: promising therapeutic targets for COVID-19 determined by systematically mutational analysis
por: Wang, Manni, et al.
Publicado: (2021)

Phase separation: from phenomenon to function
por: Woodruff, Jeffrey, et al.
Publicado: (2020)

New waves underneath the purple strain
por: Tortajada, Marta
Publicado: (2016)

Innate lymphoid cells and cancer: Role in tumor progression and inhibition
por: Yuan, Xiaodong, et al.
Publicado: (2021)

The thioredoxin system: Balancing redox responses in immune cells and tumors
por: Muri, Jonathan, et al.
Publicado: (2022)

DSSylation, a novel guide for protein degradation?
por: Gong, Cheng-Xin
Publicado: (2014)

Mining for novel antibiotics in the age of antimicrobial resistance
por: Udaondo, Zulema, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jm8qgvmva83nmfig46cn4u9tqr